Cargando…
A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response
PURPOSE: Ferroptosis and long non-coding RNA (lncRNA) expression signatures have been associated with the clinical progression and immune-contexture of different solid tumors. The study aimed to identify a prognostic signature of ferroptosis-related lncRNAs (falncRNAs) to forecast the immune scenery...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457888/ https://www.ncbi.nlm.nih.gov/pubmed/34566425 http://dx.doi.org/10.2147/IJGM.S327555 |
_version_ | 1784571200868974592 |
---|---|
author | Liu, Xiaoxiao Shi, Xiaobo Guo, Wei Ke, Yue Li, Yuxing Pan, Shupei Li, Xiaona Liu, Mei Liu, Mingzhu Wang, Yuchen Ruan, Qinli Ma, Hongbing |
author_facet | Liu, Xiaoxiao Shi, Xiaobo Guo, Wei Ke, Yue Li, Yuxing Pan, Shupei Li, Xiaona Liu, Mei Liu, Mingzhu Wang, Yuchen Ruan, Qinli Ma, Hongbing |
author_sort | Liu, Xiaoxiao |
collection | PubMed |
description | PURPOSE: Ferroptosis and long non-coding RNA (lncRNA) expression signatures have been associated with the clinical progression and immune-contexture of different solid tumors. The study aimed to identify a prognostic signature of ferroptosis-related lncRNAs (falncRNAs) to forecast the immune scenery and immunotherapy response in esophageal cancer (EC). PATIENTS AND METHODS: Gene expression profiles of EC were extracted from The Cancer Genome Atlas (TCGA) database, and ferroptosis-related genes were downloaded from the FerrDb database, which identified differentially expressed falncRNAs (DEfalncRNAs) via differential analysis. DEfalncRNA pairs associated with prognosis were identified by constructing a matrix, univariate and least absolute shrinkage and selection operator (LASSO) analysis. The prognostic signature was constructed by multivariate analysis. We appraised the forecasting capability of prognostic signature in survival, clinicopathological features, immune landscape, efficacy of immunotherapy, and drug sensitivity. The potential molecular mechanism of signature was investigated by gene set enrichment analysis (GSEA). RESULTS: We obtained 18 DEfalncRNA pairs to define a novel prognostic signature that was determined on a discovery cohort of 158 tumor samples and 11 adjacent normal tissues from TCGA and internally validated, with the definition of high- vs low-risk groups based on 3 years overall survival. We demonstrated that the high- vs low-risk groups differed for clinical parameters and computationally predicted drug sensitivity and tumor immune contexture, with the high-risk group having worse survival, more aggressive disease (node involvement, metastasis), reduced drug sensitivity, higher tumor mutation load, and gene signatures of infiltration of pro-tumoral immune cell subsets. The GSEA results revealed that ferroptosis and immunoregulatory pathways were significantly enriched in the high-risk group. CONCLUSION: The prognostic signature based on falncRNAs has the potential to forecast the survival, immune scenery, efficacy of immunotherapy, and drug sensitivity of EC, which is helpful for clinical prediction and individualized treatment. |
format | Online Article Text |
id | pubmed-8457888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84578882021-09-23 A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response Liu, Xiaoxiao Shi, Xiaobo Guo, Wei Ke, Yue Li, Yuxing Pan, Shupei Li, Xiaona Liu, Mei Liu, Mingzhu Wang, Yuchen Ruan, Qinli Ma, Hongbing Int J Gen Med Original Research PURPOSE: Ferroptosis and long non-coding RNA (lncRNA) expression signatures have been associated with the clinical progression and immune-contexture of different solid tumors. The study aimed to identify a prognostic signature of ferroptosis-related lncRNAs (falncRNAs) to forecast the immune scenery and immunotherapy response in esophageal cancer (EC). PATIENTS AND METHODS: Gene expression profiles of EC were extracted from The Cancer Genome Atlas (TCGA) database, and ferroptosis-related genes were downloaded from the FerrDb database, which identified differentially expressed falncRNAs (DEfalncRNAs) via differential analysis. DEfalncRNA pairs associated with prognosis were identified by constructing a matrix, univariate and least absolute shrinkage and selection operator (LASSO) analysis. The prognostic signature was constructed by multivariate analysis. We appraised the forecasting capability of prognostic signature in survival, clinicopathological features, immune landscape, efficacy of immunotherapy, and drug sensitivity. The potential molecular mechanism of signature was investigated by gene set enrichment analysis (GSEA). RESULTS: We obtained 18 DEfalncRNA pairs to define a novel prognostic signature that was determined on a discovery cohort of 158 tumor samples and 11 adjacent normal tissues from TCGA and internally validated, with the definition of high- vs low-risk groups based on 3 years overall survival. We demonstrated that the high- vs low-risk groups differed for clinical parameters and computationally predicted drug sensitivity and tumor immune contexture, with the high-risk group having worse survival, more aggressive disease (node involvement, metastasis), reduced drug sensitivity, higher tumor mutation load, and gene signatures of infiltration of pro-tumoral immune cell subsets. The GSEA results revealed that ferroptosis and immunoregulatory pathways were significantly enriched in the high-risk group. CONCLUSION: The prognostic signature based on falncRNAs has the potential to forecast the survival, immune scenery, efficacy of immunotherapy, and drug sensitivity of EC, which is helpful for clinical prediction and individualized treatment. Dove 2021-09-18 /pmc/articles/PMC8457888/ /pubmed/34566425 http://dx.doi.org/10.2147/IJGM.S327555 Text en © 2021 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Liu, Xiaoxiao Shi, Xiaobo Guo, Wei Ke, Yue Li, Yuxing Pan, Shupei Li, Xiaona Liu, Mei Liu, Mingzhu Wang, Yuchen Ruan, Qinli Ma, Hongbing A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response |
title | A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response |
title_full | A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response |
title_fullStr | A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response |
title_full_unstemmed | A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response |
title_short | A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA to Predict Immune Scenery and Immunotherapy Response |
title_sort | promising esophageal cancer prognostic signature of ferroptosis-related lncrna to predict immune scenery and immunotherapy response |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457888/ https://www.ncbi.nlm.nih.gov/pubmed/34566425 http://dx.doi.org/10.2147/IJGM.S327555 |
work_keys_str_mv | AT liuxiaoxiao apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT shixiaobo apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT guowei apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT keyue apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT liyuxing apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT panshupei apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT lixiaona apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT liumei apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT liumingzhu apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT wangyuchen apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT ruanqinli apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT mahongbing apromisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT liuxiaoxiao promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT shixiaobo promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT guowei promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT keyue promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT liyuxing promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT panshupei promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT lixiaona promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT liumei promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT liumingzhu promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT wangyuchen promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT ruanqinli promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse AT mahongbing promisingesophagealcancerprognosticsignatureofferroptosisrelatedlncrnatopredictimmunesceneryandimmunotherapyresponse |